Prognosis prediction for patients with cardiovascular and cerebrovascular diseases using multi-omics
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study
This study is trying to find out how different biological factors affect people with heart and brain blood vessel diseases to help doctors predict outcomes and personalize treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25000 (estimated) |
| Ages | 3 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06001073 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect clinical and biological specimen data from patients diagnosed with various cardiovascular and cerebrovascular diseases. By employing multi-omics technology, the study seeks to uncover the underlying pathogenic mechanisms of these diseases. The ultimate goal is to develop early predictive prognostic models that can inform individualized treatment strategies for affected patients. This research addresses the significant public health challenge posed by cardiovascular diseases and aims to enhance diagnosis and treatment options.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with conditions such as coronary artery disease, arrhythmias, heart valve diseases, and other specified cardiovascular and cerebrovascular diseases.
Not a fit: Patients outside the age range of 3 to 80 years, pregnant or lactating women, and those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prognostic models and personalized treatment plans for patients with cardiovascular and cerebrovascular diseases.
How similar studies have performed: While the use of multi-omics in cardiovascular research is gaining traction, this specific approach to prognosis prediction remains novel and largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are regularly visited and followed up in the appropriate patient; department. * All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases: * coronary artery disease group; * arrhythmia group; * heart valve disease group; * aortic dissection group; * cardiac masses group; * myocarditis group; * hypertension group; * cardiomyopathy group; * structural heart disease group; * ischemic cerebrovascular disease group; * hemorrhagic cerebrovascular disease group; * intracranial space occupying lesion group. Exclusion Criteria: * Age \<3 years or \>80 years old; * Pregnant and lactating women; * The patient declined to provide informed consent to participate in the study; * None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.
Where this trial is running
Xi'an, Shaanxi
- First Affiliated Hospital of Xian Jiantong University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Gouliang Li — First Affiliated Hospital Xi'an Jiaotong University
- Study coordinator: Gouliang Li
- Email: liguoliang_med@163.com
- Phone: 13759982523
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.